Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guoqin Su

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Calcified Tissue International|February 19, 2011
Clinical risk factors for recurrent fracture after hip fracture: a prospective studyCathleen S Colón-Emeric, Kenneth W Lyles, Guoqin Su, et al.
Bonekey Reports|January 15, 2014
Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label studyIan R Reid, Jacques P Brown, Naomi Levitt, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 21, 2012
Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosisSteven Boonen, Richard Eastell, Guoqin Su, et al.
The New England Journal of Medicine|September 2, 2005
Comparison of a single infusion of zoledronic acid with risedronate for Paget's diseaseIan R Reid, Paul Miller, Kenneth Lyles, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 4, 2011
A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 yearsIan R Reid, Kenneth Lyles, Guoqin Su, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 20, 2014
Subgroup variations in bone mineral density response to zoledronic acid after hip fractureJay S Magaziner, Denise L Orwig, Kenneth W Lyles, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 13, 2006
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronateDavid Hosking, Kenneth Lyles, Jacques P Brown, et al.
Malaria Journal|July 25, 2023
Prescription patterns and compliance with World Health Organization recommendations for the management of uncomplicated and severe malaria: A prospective, real-world study in sub-Saharan AfricaVito Baraka, Abel Nhama, Pedro Aide, et al.
Journal of the American Geriatrics Society|November 19, 2011
Once-yearly zoledronic acid in older men compared with women with recent hip fractureSteven Boonen, Eric Orwoll, Jay Magaziner, et al.
Malaria Journal|December 21, 2021
Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan AfricaGilles Ndayisaba, Adoke Yeka, Kwaku Poku Asante, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Calcified Tissue International|February 19, 2011
Clinical risk factors for recurrent fracture after hip fracture: a prospective studyCathleen S Colón-Emeric, Kenneth W Lyles, Guoqin Su, et al.
Bonekey Reports|January 15, 2014
Re-treatment of relapsed Paget's disease of bone with zoledronic acid: results from an open-label studyIan R Reid, Jacques P Brown, Naomi Levitt, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|March 21, 2012
Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosisSteven Boonen, Richard Eastell, Guoqin Su, et al.
The New England Journal of Medicine|September 2, 2005
Comparison of a single infusion of zoledronic acid with risedronate for Paget's diseaseIan R Reid, Paul Miller, Kenneth Lyles, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|June 4, 2011
A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 yearsIan R Reid, Kenneth Lyles, Guoqin Su, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|May 20, 2014
Subgroup variations in bone mineral density response to zoledronic acid after hip fractureJay S Magaziner, Denise L Orwig, Kenneth W Lyles, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|October 13, 2006
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronateDavid Hosking, Kenneth Lyles, Jacques P Brown, et al.
Malaria Journal|July 25, 2023
Prescription patterns and compliance with World Health Organization recommendations for the management of uncomplicated and severe malaria: A prospective, real-world study in sub-Saharan AfricaVito Baraka, Abel Nhama, Pedro Aide, et al.
Journal of the American Geriatrics Society|November 19, 2011
Once-yearly zoledronic acid in older men compared with women with recent hip fractureSteven Boonen, Eric Orwoll, Jay Magaziner, et al.
Malaria Journal|December 21, 2021
Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan AfricaGilles Ndayisaba, Adoke Yeka, Kwaku Poku Asante, et al.
Pageof 3